Blog
RSS FeedPosted by Michael Wonder on 29 Apr 2023
Prioritising patients in negotiations over drug pricing
14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...
Posted by Michael Wonder on 04 Feb 2023
NICE’s new methods reflect society’s values
4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...
Posted by Michael Wonder on 07 Nov 2022
Can we use existing guidance to support the development of robust real world evidence for health technology assessment/payer decision-making?
2 November 2022 - Advances in the digitisation of health systems and expedited regulatory approvals of innovative treatments have led to ...
Posted by Michael Wonder on 08 Sep 2022
Esketamine: NICE’s appraisal was unfair, appeal panel rules
8 September 2022 - The decision by the UK National Institute for Health and Care Excellence not to recommend esketamine ...
Posted by Michael Wonder on 06 Sep 2022
ICR criticises NICE rejection of olaparib for advanced prostate cancer
6 September 2022 - The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not ...
Posted by Michael Wonder on 17 Aug 2022
UK will not buy Evusheld owing to “insufficient data” on protection, Government says
15 August 2022 - The UK Government has said that it will not procure the COVID-19 drug Evusheld—a combination of ...
Posted by Michael Wonder on 11 Jul 2022
The (harsh) reality of real-world data external comparators for health technology assessment
8 July 2022 - We read with great interest the recently published article by Patel et al. and commend the authors ...
Posted by Michael Wonder on 25 May 2022
Target trial emulation for transparent and robust estimation of treatment effects for health technology assessment using real world data: opportunities and challenges
25 May 2022 - Evidence about the relative effects of new treatments is typically collected in randomised controlled trials. ...
Posted by Michael Wonder on 09 May 2022
Choices that fail health and wellbeing
5 May 2022 - NICE's expert group RAPID C-19, set up to ‘to ensure safe and timely patient access to treatments ...
Posted by Michael Wonder on 03 Feb 2022
Addressing uncertainty in relative effectiveness assessments by HTA organisations
31 January 2022 - This study outlines the ways in which different health technology assessment organizations deal with uncertainty in relative ...
Posted by Michael Wonder on 02 Feb 2022
Understanding innovation of health technology assessment methods: the IHTAM framework
31 January 2022 - Adequate methods are urgently needed to guarantee the good practice of health technology assessment for technologies with ...
Posted by Michael Wonder on 19 Jan 2022
UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile
19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...
Posted by Michael Wonder on 27 Nov 2021
Radical or not, NICE makes evidence based recommendations
19 November 2021 - Godlee’s call for the National Institute for Health and Care Excellence to keep close to its radical ...
Posted by Michael Wonder on 06 Oct 2021
Aetion and NICE announce collaboration to explore use of real world evidence for comparative effectiveness studies to inform clinical guidance
6 October 2021 - Collaboration will leverage the Aetion Evidence Platform to study when and how real world evidence can support ...
Posted by Michael Wonder on 18 Jul 2021
Considering and communicating uncertainty in health technology assessment
15 July 2021 - As health technology assessment seeks to combine complex sets of evidence, values, and perspectives to support open, ...